Related Articles

• Mechanisms and potential molecular markers of early response to combination epigenetic therapy in patients with myeloid malignancies
• Epigenetic treatment‑mediated modulation of PD‑L1 predicts potential therapy resistance over response markers in myeloid malignancies: A molecular mechanism involving effectors of PD‑L1 reverse signaling
• The anti-leukemic effect and molecular mechanisms of novel hydroxamate and benzamide histone deacetylase inhibitors with 5-aza-cytidine
• The HDAC inhibitor, panobinostat, induces apoptosis by suppressing the expresssion of specificity protein 1 in oral squamous cell carcinoma
• Pharmacological inhibition of EZH2 combined with DNA‑damaging agents interferes with the DNA damage response in MM cells